In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GL ...

The Biden administration has proposed a new plan to expand coverage of glucagon-like peptide-1 (GLP-1) medications such as ...

In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

In a subgroup analysis, there was a positive effect in people with obesity, with significant reductions in brain reward center cue reactivity on functional magnetic resonance imaging. (HealthDay ...

TennCare is federally required to cover GLP-1 drugs; of the $118M in the cost increase request, more than $76 million would ...

However, authors caution there is little high-quality evidence. (HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in ...